Correlation of tumour markers in ascitic fluid and serum: Are measurements of ascitic tumour markers a futile attempt?

Journal of International Medical Research

Volumn 37, Issue 1, 2009, Pages 79-86

  Tuzun, Yekta ^a   Celik Y ^a   Bayan, K ^a   Yilmaz, S ^a   Dursun, M ^a   Canoruc, F ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Ascites; Correlation; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; ARTICLE; ASCITES FLUID ANALYSIS; ASCITES TUMOR; BENIGN TUMOR; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PROTEIN BLOOD LEVEL; ASCITES; ASCITES FLUID; BLOOD; CHEMISTRY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; NEOPLASM;

ASCITES; ASCITIC FLUID; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 64149095861     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700109     Document Type: Article

References (24)

1. Runyon BA: Care of patients with ascites. N Engl J Med 1994; 330: 337-342.
2. Runyon BA: Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management (Feldman M, Friedman LS, Brandt LJ, eds), 8th edn, vol 2. Philadelphia: Saunders Elsevier, 2006; pp 1935-1964.
3. Motherby H, Nadjari B, Friegel P, et al: Diagnostic accuracy of effusion cytology. Diagn Cytopatho; 1999; 20: 350-357.
4. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 89: 1456-1466.
5. Mezget J, Permanetter W, Gerbes AL, et al: Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol 1988; 41: 633-643.
6. Loewenstein MS, Rittgers RA, Feinerman AE, et al: Carcinoembryonic antigen assay of ascites and detection of malignancy. Ann Intern Med 1978; 89: 635-638.
7. Chen SJ, Wang SS, Lu CW, et al: Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy related ascites. J Gastroenterol Hepatol 1994; 9: 396-400.
8. Sari R, Yildirim B, Sevinc A, et al: The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9 and CA 15-3 levels in differential diagnosis of ascites etiology. Hepatogastroenterology 2001; 49: 1616-1621.
9. Crespi S, Vilimelis J, Moragues M, et al: El diagnostico de malignidad en los detrames serosos mediante el uso marcadores tumorales: utilidad de la determinacion simultanea (liquido/suero) In: Biologia y Utilidad Clinica de los Marcadores Tumorales (Molina R, Ballesta AM, eds), vol 1. Sant Quirze del Valles: Grafiques Sant Quirze, 1999, pp 40 - 242 [in Spanish].
10. Braun HV, Dutter LE, Zaeske M: Statistical significance of carcinoembryonic antigen in plasma and pleural fluid. Surgery 1992; 92: 561-562.
11. Bland JM: An Introduction to Medical Statistics, 3rd edn. Oxford: Oxford University Press, 2000.
12. Shitrit D, Zingerman B, Shitrit AB, et al: Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005; 10: 501-507.
13. Alatas F, Alatas O, Metintas M, et al: Diagnostic value of CEA, CA 15-3, CA-19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001; 31: 9-16.
14. Trape J, Molina R, Sant F: Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol 2004; 25: 276-281.
15. Gulyas M, Kaposi AD, Elek G, et al: Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology. J Clin Pathol 2001; 54: 831-835.
16. Azmi M, Ghanavati M, Keramati MR, et al: Serum and ascitic fluid CA-125 level in patients with ascites. Indian J Gastroenterol 2007; 26: 45-46.
17. Molina R, Filella X, Bruix J, et al: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991; 7: 1379-1383.
18. Mackay AM, Tracy RP, Craighead JE: Cytokeratin expression in rat mesothelial cells in vitro is controlled by the extracellular matrix. J Cell Sci 1990; 95: 97-107.
19. Zellemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, et al: CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994; 47: 263-265.
20. Martinez-Vea A, Gatell JM, Segura F, et al: Diagnostic value of tumoral markers in serous effusions: carcinoembryonic antigen, alpha1-acidglycoprotein, alpha-fetoprotein, phosphohexose isomerase and beta2-microglobulin. Cancer 1982; 50: 1783-1788.
21. Kalambokis G, Kostoula A, Economou M, et al: Tumor necrosis factor-α-related intraperitoneal release of CA 125 in cirrhotic patients with sterile ascites. Clin Chem 2005; 51: 2207-2208.
22. Pihko H, Ruoslahti E: Alfa-fetoprotein production in normal and regenerating mouse liver. Colloq Inst Natl Sante Rech Med 1974; 28: 333-336.
23. Ritts RE, Del Villano BC, Chi VL, et al: Initial clinical evaluation of an immunoradiometric assay for CA 19.9 using the NCI serum bank. Int J Cancer 1984; 33: 339-345.
24. Shuster J, Silverman M, Gold P: Metabolism of human carcinoembryonic antigen in xenogeneic animals. Cancer Res 1973; 33: 65-68.